Levothyroxine Sodium description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Levothyroxine Sodium

REMEDYREPACK INC.


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

BOXED WARNING

WARNING:
Thyroid hormones, including Levothyroxine sodium tablets, USP, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.


LEVOTHYROXINE SODIUM DESCRIPTION



Levothyroxine Sodium




Inactive Ingredients



CLINICAL PHARMACOLOGY






INDICATIONS AND USAGEPRECAUTIONSDOSAGE AND ADMINISTRATION

PHARMACOKINETICS

AbsorptionPRECAUTIONS, Drug InteractionsDrug-Food Interactions
DistributionPRECAUTIONS, Drug InteractionsDrug-Laboratory Test InteractionsPRECAUTIONS, Pregnancy
MetabolismTable 1
Elimination




INDICATIONS & USAGE


Hypothyroidism
Pituitary TSH SuppressionWARNINGSPRECAUTIONSWARNINGSPRECAUTIONSWARNINGSPRECAUTIONS

LEVOTHYROXINE SODIUM CONTRAINDICATIONS

PRECAUTIONSDESCRIPTION, Inactive Ingredients

WARNINGS

WARNING:
Thyroid hormones, including Levothyroxine sodium tablets, USP, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.



CONTRAINDICATIONS

PRECAUTIONS

General
Drug Interactions
Effects on bone mineral density-
Patients with underlying cardiovascular disease-WARNINGSPRECAUTIONS, Geriatric UseDOSAGE AND ADMINISTRATION
Patients with nontoxic diffuse goiter or nodular thyroid disease-WARNINGSCONTRAINDICATIONS

Associated endocrine disorders
PRECAUTIONS, Autoimmune polyglandular syndrome

Autoimmune polyglandular syndrome
PRECAUTIONS, Drug Interactions

Other associated medical conditions


INFORMATION FOR PATIENTS

















LABORATORY TESTS



PRECAUTIONS, Drug InteractionsDrug-Laboratory Test Interactions

WARNINGSPRECAUTIONSDOSAGE AND ADMINISTRATION

PRECAUTIONS, Pediatric UseDOSAGE AND ADMINISTRATION



DRUG INTERACTIONS




Table 2
Table 2

Table 2






PEDIATRIC USE



DOSAGE AND ADMINISTRATIONTable 3PRECAUTIONS, Laboratory Tests


PRECAUTIONS
PRECAUTIONS, Laboratory TestsDOSAGE and ADMINISTRATION







GERIATRIC USE

WARNINGSPRECAUTIONSDOSAGE AND ADMINISTRATION

LEVOTHYROXINE SODIUM ADVERSE REACTIONS

PRECAUTIONSOVERDOSAGE
General:
Central nervous system:
Musculoskeletal:
Cardiovascular:
Respiratory:
Gastrointestinal:
Dermatologic:
Endocrine:
Reproductive:





OVERDOSAGE

PRECAUTIONSADVERSE REACTIONS

Treatment of Overdosage

Acute Massive Overdosage

DOSAGE & ADMINISTRATION

General Principles
WARNINGSPRECAUTIONSPRECAUTIONS, Laboratory Tests
PRECAUTIONS, Drug InteractionsInformation for Patients

PRECAUTIONS

Specific Patient Populations
WARNINGSPRECAUTIONS, Laboratory Tests




PRECAUTIONS, Laboratory Tests


PRECAUTIONS, Pediatric Use
PRECAUTIONS , Drug-Food Interactions



Table 3


PRECAUTIONS, Laboratory TestsPediatric UsePregnancy



CONTRAINDICATIONSWARNINGSPRECAUTIONS


HOW SUPPLIED



















































STORAGE AND HANDLING



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION














Levothyroxine Sodium



Levothyroxine Sodium



Levothyroxine Sodium

Levothyroxine Sodium TABLET

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:49349-628(NDC:0781-5182)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
LEVOTHYROXINE SODIUM LEVOTHYROXINE 0.075 mg

Inactive Ingredients

Ingredient Name Strength
MAGNESIUM STEARATE
cellulose, microcrystalline
SILICON DIOXIDE
SODIUM STARCH GLYCOLATE TYPE A POTATO

Product Characteristics

Color Size Imprint Code Shape
purple 9 mm 75;GG;333 BULLET

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:49349-628-02 30 in 1 BLISTER PACK

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA021342 2011-12-07


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.